MX2024004762A - Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r. - Google Patents

Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.

Info

Publication number
MX2024004762A
MX2024004762A MX2024004762A MX2024004762A MX2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A MX 2024004762 A MX2024004762 A MX 2024004762A
Authority
MX
Mexico
Prior art keywords
methods
antagonist
administering
prurigo nodularis
treating
Prior art date
Application number
MX2024004762A
Other languages
English (en)
Spanish (es)
Inventor
Ashish Bansal
Heribert Staudinger
Elizabeth Laws
Naimish Patel
John O''MALLEY
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2024004762A publication Critical patent/MX2024004762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004762A 2021-10-20 2022-10-19 Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r. MX2024004762A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163257876P 2021-10-20 2021-10-20
US202263300492P 2022-01-18 2022-01-18
EP22315048 2022-03-04
PCT/US2022/078341 WO2023069976A1 (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
MX2024004762A true MX2024004762A (es) 2024-05-08

Family

ID=84329583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004762A MX2024004762A (es) 2021-10-20 2022-10-19 Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.

Country Status (10)

Country Link
US (1) US20230183362A1 (https=)
EP (1) EP4419557A1 (https=)
JP (1) JP2024539148A (https=)
KR (1) KR20240099290A (https=)
CN (1) CN119137149A (https=)
AU (1) AU2022369296A1 (https=)
CA (1) CA3235380A1 (https=)
IL (1) IL312187A (https=)
MX (1) MX2024004762A (https=)
WO (1) WO2023069976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
IL293487A (en) * 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20230374144A1 (en) 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof

Also Published As

Publication number Publication date
US20230183362A1 (en) 2023-06-15
JP2024539148A (ja) 2024-10-28
WO2023069976A1 (en) 2023-04-27
EP4419557A1 (en) 2024-08-28
IL312187A (en) 2024-06-01
CN119137149A (zh) 2024-12-13
AU2022369296A1 (en) 2024-05-30
CA3235380A1 (en) 2023-04-27
KR20240099290A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
MX387530B (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña.
MX2022011730A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2022014440A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
MY163953A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
WO2015006571A8 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
EA201590210A1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
MX2025005113A (es) Metodos para tratar la dermatitis de manos y pies mediante la administracion de un antagonista de il-4r
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
MX2022007958A (es) Metodos para tratar o prevenir el asma alergica mediante la administracion de un antagonista de il-33 y/o un antagonista de il-4r.
MX2024002072A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX2025011152A (es) Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EA202190966A1 (ru) Пролекарства антагонистов cgrp
MX2025011114A (es) Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r
MX2024012345A (es) Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r